Pfizer Ends Licensing Pacts For Pulmonary Drug, HIV Therapy, Citing Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer is terminating a development deal with Altana for the pulmonary agent Daxas (roflumilast) after one-year data from a Phase III study met only one of two primary endpoints, the firms announced July 1.